DE602006010870D1 - Als antagonisten von histamin h3 geeignete piperidinderivate - Google Patents

Als antagonisten von histamin h3 geeignete piperidinderivate

Info

Publication number
DE602006010870D1
DE602006010870D1 DE602006010870T DE602006010870T DE602006010870D1 DE 602006010870 D1 DE602006010870 D1 DE 602006010870D1 DE 602006010870 T DE602006010870 T DE 602006010870T DE 602006010870 T DE602006010870 T DE 602006010870T DE 602006010870 D1 DE602006010870 D1 DE 602006010870D1
Authority
DE
Germany
Prior art keywords
histamine
antagonists
piperidine derivatives
suited
derivatives suited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010870T
Other languages
English (en)
Inventor
Robert G Aslanian
Michael Y Berlin
Christopher W Boyce
Jianhua Chao
Lera Ruiz Manuel De
Pietro Mangiaracina
Kevin D Mccormick
Mwangi W Mutahi
Stuart B Rosenblum
Neng-Yang Shih
Daniel M Solomon
Wing C Tom
Henry A Vaccaro
Junying Zheng
Xiaohong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602006010870D1 publication Critical patent/DE602006010870D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
DE602006010870T 2005-06-20 2006-06-19 Als antagonisten von histamin h3 geeignete piperidinderivate Active DE602006010870D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69211005P 2005-06-20 2005-06-20
PCT/US2006/023800 WO2007001975A1 (en) 2005-06-20 2006-06-19 Piperidine derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
DE602006010870D1 true DE602006010870D1 (de) 2010-01-14

Family

ID=36968725

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006010870T Active DE602006010870D1 (de) 2005-06-20 2006-06-19 Als antagonisten von histamin h3 geeignete piperidinderivate

Country Status (17)

Country Link
US (2) US7635705B2 (de)
EP (1) EP1902046B1 (de)
JP (1) JP2008546784A (de)
KR (1) KR20080021082A (de)
CN (1) CN101243072A (de)
AR (1) AR054787A1 (de)
AT (1) ATE450526T1 (de)
AU (1) AU2006262441A1 (de)
CA (1) CA2610959A1 (de)
DE (1) DE602006010870D1 (de)
ES (1) ES2337727T3 (de)
HK (1) HK1121737A1 (de)
IL (1) IL187984A0 (de)
MX (1) MX2008000115A (de)
TW (1) TW200738676A (de)
WO (1) WO2007001975A1 (de)
ZA (1) ZA200710968B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
KR20080081321A (ko) * 2005-12-21 2008-09-09 쉐링 코포레이션 Ｈ3 길항제/역 작용제 및 식욕 억제제의 조합물
EA200900539A1 (ru) * 2006-10-20 2009-10-30 Эрет Терэпьютикс, Инк. Соединения фенилмочевины (варианты), содержащая их фармацевтическая композиция и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой (варианты)
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP2010516787A (ja) * 2007-01-29 2010-05-20 アレテ セラピューティクス， インコーポレイテッド 代謝症候群および関連障害の処置のための可溶性エポキシドヒドロラーゼ阻害剤
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CA2679807A1 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidine derivatives and methods of use thereof
AU2007349176A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
AU2008240729B2 (en) 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CN101663292A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
EP2141994A4 (de) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals Mehrringverbindungen und ihre verwendungen
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
RU2502734C2 (ru) 2008-07-03 2013-12-27 Янссен Фармацевтика Нв Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP2307374B1 (de) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten
EP2404902A1 (de) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidin- und pyrrolidinderivate mit npy-y5-rezeptorantagonismus
US8337835B2 (en) * 2009-04-10 2012-12-25 Washington University Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
ES2601007T3 (es) * 2010-01-22 2017-02-13 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que presenta un efecto inhibidor de PGDS
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
US20140288169A1 (en) * 2011-01-07 2014-09-25 Targacept, Inc. Nicotinic receptor non-competitive antagonists
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
KR101974675B1 (ko) 2011-09-16 2019-05-02 갈렉틴 테라퓨틱스, 인크. 비알콜성 지방간염 및 비알콜성 지방간 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN102657868A (zh) * 2012-05-30 2012-09-12 中国药科大学 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN109082465A (zh) * 2018-08-20 2018-12-25 苏州市广济医院 奥氮平诱导糖代谢紊乱相关疾病的分子标志物及其用途
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US661145A (en) * 1900-08-06 1900-11-06 Otto Hausmann Attachment for bicycles.
US856473A (en) * 1906-05-21 1907-06-11 Daniel E Krause Drilling-machine.
US4983567A (en) * 1987-03-16 1991-01-08 Biomeasure, Inc. Immunomodulators and methods of making same
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
TW223059B (de) 1991-07-23 1994-05-01 Schering Corp
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
EP0707567B1 (de) 1993-07-09 2001-09-12 Schering Corporation Verfahren zur herstellung von azetidinonen
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
CZ43299A3 (cs) 1996-08-16 1999-07-14 Schering Corporation Léčba alergií horních cest dýchacích kombinací antagonistů histaminového receptoru
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
AU4692399A (en) * 1998-06-17 2000-01-05 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
CN1210274C (zh) 2000-02-11 2005-07-13 沃泰克斯药物股份有限公司 哌嗪和哌啶衍生物
US20020045686A1 (en) 2000-08-24 2002-04-18 The Yokohama Rubber Co., Ltd Rubber composition having improved wet skid resistance and rolling resistance
DE10042447A1 (de) 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS50864B (sr) 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
JP2004516289A (ja) 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジフェニルアゼチジノン誘導体、その調製方法、その化合物を含む薬剤およびその使用
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CN1298715C (zh) 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
KR100590342B1 (ko) 2001-03-28 2006-06-15 쉐링 코포레이션 아제티딘온 중간체 화합물의 에난티오-선택적 합성법
US20030137689A1 (en) * 2002-01-18 2003-07-24 General Instrument Corporation. Remote printer driver server
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
NZ535763A (en) * 2002-04-18 2007-06-29 Schering Corp (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists
EP1494671B1 (de) * 2002-04-18 2011-10-19 Schering Corporation 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU2003243709B2 (en) 2002-06-24 2007-01-18 Schering Corporation Indole derivatives useful as histamine H3 antagonists
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CN1330667C (zh) 2002-08-06 2007-08-08 塞诺菲-安万特德国有限公司 分离肠胆固醇结合蛋白的方法
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
DK1615909T3 (da) * 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
GB0315360D0 (en) 2003-07-01 2003-08-06 Burns Robert N Anti-theft device
AU2003259547A1 (en) 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
WO2005021495A2 (en) 2003-08-25 2005-03-10 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
WO2005021497A2 (en) 2003-08-28 2005-03-10 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
GB0321228D0 (en) 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
BRPI0414812A (pt) 2003-09-26 2006-11-14 Forbes Medi Tech Inc método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
EP1522541A1 (de) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
US20070135357A1 (en) 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2005046662A2 (en) 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
EA010026B1 (ru) 2003-11-10 2008-06-30 Майкробиа, Инк. 4-биарилил-1-фенилазетидин-2-оны
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN100471835C (zh) 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ES2337727T3 (es) 2010-04-28
CN101243072A (zh) 2008-08-13
TW200738676A (en) 2007-10-16
ATE450526T1 (de) 2009-12-15
KR20080021082A (ko) 2008-03-06
EP1902046A1 (de) 2008-03-26
AR054787A1 (es) 2007-07-18
WO2007001975A1 (en) 2007-01-04
ZA200710968B (en) 2009-03-25
IL187984A0 (en) 2008-03-20
US20070015807A1 (en) 2007-01-18
CA2610959A1 (en) 2007-01-04
HK1121737A1 (en) 2009-04-30
MX2008000115A (es) 2008-03-18
AU2006262441A1 (en) 2007-01-04
EP1902046B1 (de) 2009-12-02
US7846946B2 (en) 2010-12-07
JP2008546784A (ja) 2008-12-25
US20090286830A1 (en) 2009-11-19
WO2007001975A8 (en) 2008-01-24
US7635705B2 (en) 2009-12-22

Similar Documents

Publication Publication Date Title
DE602006010870D1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE344798T1 (de) Als histamin-h3-antagonisten geeignete indolderivate
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
ATE448217T1 (de) Substituierte piperidine als renin-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
ATE414698T1 (de) Durch 5gliedrige heterocyclen substituierte mtp- inhibierende arylpiperidine oder -piperazine
DE60319813D1 (de) 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE60320529D1 (de) Chinolinderivate als npy antagonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE427299T1 (de) Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren
ATE479681T1 (de) Substituierte piperidine
ATE471321T1 (de) Substituierte piperidine als renin-inhibitoren
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition